Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples Post author:Sam Post published:March 13, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal's Agensys, Inc. July 26, 2017 Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017 Bay Area's Tricia Closes $57.5M Series D, Pushes Into Phase III Trial November 7, 2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017